Published in Blood on May 15, 2002
Mesenchymal Stem Cell Therapy for Liver Cirrhosis | NCT03626090
Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A (2005) 6.16
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol (2010) 4.03
Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med (2007) 3.64
Organization of immunological memory by bone marrow stroma. Nat Rev Immunol (2010) 3.57
IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 3.53
Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal (2011) 3.31
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood (2006) 3.16
A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One (2010) 3.14
Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) (2005) 3.00
Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med (2010) 2.86
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng (2010) 2.66
Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol (2007) 2.65
Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol (2009) 2.60
Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transplant (2010) 2.50
Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis. J Immunol (2009) 2.37
Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med (2013) 2.34
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther (2010) 2.29
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci U S A (2010) 2.27
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med (2005) 2.21
Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells (2012) 2.14
Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc Res (2010) 2.06
Granulomas of intestinal tuberculosis and Crohn's disease can be differentiated by CD73 cell surface marker expression: a pilot study. Dig Dis Sci (2013) 2.05
Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2008) 1.98
Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther (2010) 1.95
How mesenchymal stem cells interact with tissue immune responses. Trends Immunol (2012) 1.92
Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther (2010) 1.90
Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol (2014) 1.90
Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica (2008) 1.87
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem (2010) 1.86
Clinical applications of mesenchymal stem cells. J Hematol Oncol (2012) 1.86
Derivation and immunological characterization of mesenchymal stromal cells from human embryonic stem cells. Exp Hematol (2008) 1.80
Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol (2011) 1.73
Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes (2010) 1.69
Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc (2011) 1.66
Mesenchymal stem cells for bone repair and metabolic bone diseases. Mayo Clin Proc (2009) 1.59
Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res (2015) 1.57
Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury. J Neuroinflammation (2013) 1.53
Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med (2010) 1.53
MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells (2013) 1.51
Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol (2012) 1.50
Mesenchymal stem cells migration homing and tracking. Stem Cells Int (2013) 1.49
Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. J Cell Mol Med (2009) 1.49
The immunomodulatory activity of human umbilical cord blood-derived mesenchymal stem cells in vitro. Immunology (2008) 1.46
Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med (2013) 1.44
Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants. Stem Cells Dev (2012) 1.44
Combinatorial Intervention with Mesenchymal Stem Cells and Granulocyte Colony-Stimulating Factor in a Rat Model of Ulcerative Colitis. Dig Dis Sci (2015) 1.44
Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med (2009) 1.42
Lung resident mesenchymal stem cells isolated from human lung allografts inhibit T cell proliferation via a soluble mediator. J Immunol (2008) 1.42
Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury. J Neurotrauma (2012) 1.41
Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol (2010) 1.41
Allogeneic periodontal ligament stem cell therapy for periodontitis in swine. Stem Cells (2010) 1.40
Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol (2012) 1.39
Reduction of acute rejection by bone marrow mesenchymal stem cells during rat small bowel transplantation. PLoS One (2014) 1.39
Early transplantation of human immature dental pulp stem cells from baby teeth to golden retriever muscular dystrophy (GRMD) dogs: Local or systemic? J Transl Med (2008) 1.38
Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair (2008) 1.37
Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther (2005) 1.37
Potential application of mesenchymal stem cells in acute lung injury. Expert Opin Biol Ther (2009) 1.36
Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS One (2008) 1.36
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther (2007) 1.35
Concise review: Bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications. Stem Cells (2011) 1.34
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A (2009) 1.34
Bone marrow-derived mesenchymal stromal cells inhibit Th2-mediated allergic airways inflammation in mice. Stem Cells (2011) 1.33
Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in mice. Clin Exp Immunol (2008) 1.32
Wharton's jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci (2013) 1.31
Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol (2012) 1.31
Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One (2009) 1.31
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. J Extracell Vesicles (2015) 1.30
MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation. Stem Cells Int (2013) 1.30
Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells. Immunol Cell Biol (2013) 1.29
Mesenchymal lineage stem cells have pronounced anti-inflammatory effects in the twitcher mouse model of Krabbe's disease. Stem Cells (2011) 1.29
Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells (2014) 1.29
Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 1.28
Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther (2010) 1.28
Transplants of human mesenchymal stem cells improve functional recovery after spinal cord injury in the rat. Cell Mol Neurobiol (2006) 1.28
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos Trans R Soc Lond B Biol Sci (2005) 1.26
Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther (2009) 1.24
Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest (2015) 1.24
New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther (2010) 1.24
Mesenchymal stem cells in tumor development: emerging roles and concepts. Cell Adh Migr (2012) 1.24
Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells. Regen Med (2011) 1.21
Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci (2011) 1.20
Emerging roles for multipotent, bone marrow-derived stromal cells in host defense. Blood (2012) 1.20
The stem cell secretome and its role in brain repair. Biochimie (2013) 1.19
Optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron oxide nanoparticles and in vivo visualization by magnetic resonance imaging. J Nanobiotechnology (2011) 1.19
Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev (2010) 1.18
Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation (2007) 1.18
Clinical applications of mesenchymal stem cells. Korean J Intern Med (2013) 1.18
Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects. Tissue Eng Part A (2012) 1.18
Multipotent stromal cells skew monocytes towards an anti-inflammatory interleukin-10-producing phenotype by production of interleukin-6. Haematologica (2013) 1.17
Role of mesenchymal stromal cells in solid organ transplantation. Transplant Rev (Orlando) (2008) 1.17
Analysis of in vitro secretion profiles from adipose-derived cell populations. J Transl Med (2012) 1.17
Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med (2011) 1.17
Transplantation of canine umbilical cord blood-derived mesenchymal stem cells in experimentally induced spinal cord injured dogs. J Vet Sci (2007) 1.16
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med (2011) 4.50
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol (2004) 2.36
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica (2002) 2.34
Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol (2013) 1.99
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood (2006) 1.57
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica (2008) 1.54
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol (2008) 1.54
Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica (2006) 1.53
Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol (2009) 1.47
Histologic basis of variations in retinal pigment epithelium autofluorescence in eyes with geographic atrophy. Ophthalmology (2013) 1.43
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol (2010) 1.42
Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol (2007) 1.41
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 1.40
Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology (2008) 1.37
Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res (2010) 1.28
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells. Blood (2003) 1.27
Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol (2006) 1.25
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res (2009) 1.22
Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol (2006) 1.20
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood (2003) 1.18
Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol (2002) 1.18
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica (2013) 1.18
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol (2008) 1.10
Targeting TRAIL agonistic receptors for cancer therapy. Clin Cancer Res (2007) 1.10
Early postoperative safety and surgical outcomes after implantation of a suprachoroidal micro-stent for the treatment of open-angle glaucoma concomitant with cataract surgery. J Cataract Refract Surg (2013) 1.08
Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood (2002) 1.07
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife (2013) 1.06
Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol (2008) 1.05
Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol (2011) 1.04
Testing the effects of the dye acid violet-17 on retinal function for an intraocular application in vitreo-retinal surgery. Graefes Arch Clin Exp Ophthalmol (2014) 1.03
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series. Graefes Arch Clin Exp Ophthalmol (2013) 0.99
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol (2005) 0.99
Compound subretinal prostheses with extra-ocular parts designed for human trials: successful long-term implantation in pigs. Graefes Arch Clin Exp Ophthalmol (2007) 0.97
The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol (2007) 0.97
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol (2008) 0.97
Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. Br J Haematol (2009) 0.96
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol (2002) 0.96
Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer (2005) 0.96
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res (2004) 0.95
Radioimmunotherapy for stem cell transplantation in non-Hodgkin's lymphoma: in pursuit of a complete response. Oncologist (2009) 0.95
HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med (2008) 0.95
Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood (2010) 0.92
High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol (2004) 0.91
Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol (2006) 0.91
Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res (2003) 0.91
Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration. Retina (2007) 0.91
Phase II study of sorafenib in patients with relapsed or refractory lymphoma. Br J Haematol (2012) 0.91
Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res (2008) 0.91
Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res (2012) 0.90
Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol (2013) 0.89
Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. Eur J Cancer (2012) 0.89
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol (2005) 0.89
Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: a pilot study. Acta Ophthalmol (2011) 0.89
Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. Br J Ophthalmol (2007) 0.89
Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. Leuk Res (2002) 0.88
Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica (2012) 0.88
Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept. Cell Physiol Biochem (2016) 0.88